We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

News

News

Phase 1 ALS Trial is First to Test Antisense Treatment of Neurodegenerative Disease

No serious adverse effects seem from central-nervous-system infusion of drug that blocks mutated protein.
News

Cellular Gatekeepers Do More than Open Doors for Drugs, UCSF Study Finds

Discovery could change the way we design medications and shed light on side effects.
News

Biobanking Market to Reach $24.4bn in 2017

Further growth expected to 2023, predicts visiongain in new report.
News

Regeneron Pharmaceuticals Announces Expansion in New York's Hudson Valley

Regeneron Pharmaceuticals, Inc. announced that the Company will expand the Regeneron corporate headquarters and laboratories in Westchester County and create more than 400 new high-skill jobs.
News

Abcam Licenses Novel Technology from Columbia University for Neurobiological Research

New products from Abcam Biochemicals will support research into neurodegeneration and drug addiction.
News

Pall to Open Latest Life Sciences Centre of Excellence in Portsmouth (UK)

The Centre of Excellence (COE) will offer a full suite of capabilities including cell culture, purification, analytical solutions, protein characterization and microbiological tools.
News

Azbil BioVigilant (ABV) Announces Partnership with University of Tennessee (UT) Pharmacy College

UT to implement ABV’s rapid microbial monitoring in new aseptic processing area.
News

A Molecular-Modeling Toolbox Aimed at Bridging the Gap Between Medicinal Chemistry and Computational Sciences

Researchers from the University of Basel have designed a versatile single-click tools to assist medicinal chemists in performing two routine modeling tasks.
News

Life Sciences Index Present Pharma Integrates 2013

Strategically transforming Pharma business relationships.
News

Canbex Therapeutics Completes £2.1m ($3.2m) Financing Round

Fundraising will enable the Company to complete the early development of its lead candidate for the treatment of spasticity in multiple sclerosis (MS).
Advertisement